Literature DB >> 32700669

All-cause excess mortality observed by age group and regions in the first wave of the COVID-19 pandemic in England.

Mary A Sinnathamby1, Heather Whitaker1, Laura Coughlan1, Jamie Lopez Bernal1, Mary Ramsay1, Nick Andrews1.   

Abstract

England has experienced one of the highest excess in all-cause mortality in Europe during the current COVID-19 pandemic. As COVID-19 emerged, the excess in all-cause mortality rapidly increased, starting in March 2020. The excess observed during the pandemic was higher than excesses noted in the past 5 years. It concerned all regions and all age groups, except the 0-14 year olds, but was more pronounced in the London region and in those aged ≥ 85 years.

Entities:  

Keywords:  COVID-19 pandemic; EuroMOMO; all-cause mortality

Mesh:

Year:  2020        PMID: 32700669      PMCID: PMC7376843          DOI: 10.2807/1560-7917.ES.2020.25.28.2001239

Source DB:  PubMed          Journal:  Euro Surveill        ISSN: 1025-496X


Excess all-cause mortality has traditionally been noted during the winter months in England, with extreme cold weather and circulation of seasonal influenza, being some of the main contributors for winter excesses [1-4]. High excess mortality levels were previously observed in England in the 2014/15 and 2017/18 seasons, which coincided with influenza seasons dominated by influenza A(H3N2), a subtype known to affect the older population (≥ 65 years of age) [2,4]. The 2019/20 influenza season has been dominated by the circulation of influenza A(H3N2), with an early start (breaching expected levels in week 47, 18–24 November, 2019) [5]. Excess mortality was observed when influenza activity was at its highest but subsequently decreased below expected levels in mid-January [6]. Subsequently, in late January, the first cases of coronavirus disease (COVID-19) were detected. A rapid increase in excess all-cause mortality was observed approximately 2 weeks after the announcement of the first COVID-19 confirmed death on 5 March 2020. This study describes the exceptionally high all-cause excess mortality which has been observed during the COVID-19 pandemic in England, up to calendar week 20 (week ending 17 May 2020).

Monitoring excess all-cause mortality

All-cause excess mortality is routinely monitored in England, using the European monitoring of excess mortality (EuroMOMO) algorithm, which was initiated to allow for timely comparisons across European countries for public health action [7]. The algorithm uses observed weekly deaths, by week of death from the past 5 years, and applies a correction for delay from death to registration based on historic delays. A baseline expected count is calculated from a Serfling model with a trend fitted using an over-dispersed Poisson distribution and the excess and corresponding standard deviations (z-scores) above the baseline calculated [8]. Daily aggregated all-cause death registrations in England are collected from the General Registry Office including information on date of death, date of registration, sex, age and Public Health England (PHE) regions. The analysis in this report is based on registrations until 02 June 2020 and shows deaths until the end of week 20 2020 (17 May 2020). The following age groups were used: 0–14 years, 15–44 years, 45–64 years, 65–74 years, 75–84 years and ≥ 85 years. The data were also examined by the four PHE regions [9]. Cumulative excess all-cause mortality rates were calculated using annual population estimates from the Office for National Statistics (ONS) [10]. All statistical analyses were carried out in STATA v15.1 (StataCorp, TX).

Estimates of excess all-cause mortality

England has experienced much higher all-cause excess mortality in the 2019/20 season when comparing excess mortality observed in the past 5 years (Figure 1).
Figure 1

Overall excess all-cause mortality in all ages (A) by number of deaths and predominant circulating influenza subtype and (B) by z-score, calendar week 40 2015 to 20 2020

Overall excess all-cause mortality in all ages (A) by number of deaths and predominant circulating influenza subtype and (B) by z-score, calendar week 40 2015 to 20 2020 All age all-cause mortality increased rapidly, exceeding expected levels from week 12 2020 and peaking in week 15 2020 (with 12,045 estimated excess deaths and a z-score of 41.6). An amount of 56,456 all-cause excess deaths was estimated between week 12 2020 and week 20 2020 (Figure 1). The cumulative all-cause excess mortality rate between weeks 10 and 20 was 100.83 per 100,000 population with an observed-to-expected mortality ratio of 1.54, exceeding cumulative rates and ratios observed in any full seasons (Table).
Table

Cumulative estimated all-cause excess mortality rates per 100,000 population and observed/expected mortality ratios, calendar week 40 2015–week 20 2020

CriteriaCrude excess mortality rate (observed/expected ratio) in weeks 40 to 20 each season
2015/162016/172017/182018/192019/20: week 40 to 092019/20: week 10 to 20
Age group
All ages0.95 (1.00)21.72 (1.04)48.73 (1.08)−2.65 (1.00)13.20 (1.02)100.83 (1.54)
0–14 years0.25 (1.01)0.90 (1.04)0.45 (1.02)0.31 (1.02)0.74 (1.06)0.33 (1.05)
15–44 years−1.78 (0.96)−0.24 (0.99)1.82 (1.04)0.41 (1.01)−1.34 (0.95)5.79 (1.46)
45–64 years2.82 (1.01)0.62 (1.00)15.25 (1.06)2.52 (1.01)3.89 (1.02)41.08 (1.47)
65–74 years0.83 (1.00)25.05 (1.03)58.87 (1.06)6.34 (1.01)8.69 (1.01)131.65 (1.42)
75–84 years32.06 (1.01)98.98 (1.03)205.01 (1.07)−17.16 (0.99)77.19 (1.04)508.77 (1.58)
≥ 85 years−18.87 (1.00)554.24 (1.06)1,061.71 (1.11)−160.23 (0.98)280.17 (1.04)1,767.16 (1.59)
PHE regions
North3.24 (1.00)21.75 (1.03)48.80 (1.08)−9.09 (0.99)11.68 (1.03)105.49 (1.50)
Midlands and East−1.91 (1.00)22.07 (1.04)48.51 (1.09)−1.24 (1.00)15.39 (1.04)92.00 (1.53)
London3.19 (1.01)15.70 (1.04)33.72 (1.09)4.69 (1.01)12.80 (1.05)122.77 (2.06)
South5.24 (1.01)24.16 (1.04)51.19 (1.08)−5.76 (0.99)16.79 (1.04)94.89 (1.44)

PHE: Public Health England.

PHE: Public Health England. By age group, high levels of excess mortality, exceeding 8 z-scores above baselines, were evident in all but the 0–14 year olds. The highest excess in deaths was observed in those ≥ 85 years old, with cumulative mortality rates in the latter weeks of the 2019/20 season, exceeding those observed in the past 5 years including the 2017/18 season (Figure 2). Decreases in deaths since the peak week have been slow in this age group compared with decreases in other age groups. Similar observations were seen in the 75–84 year olds but with more rapid decreases from the peak. Observed and delay-corrected numbers of deaths were similar in older age (≥ 65 years of age) groups, but in younger age groups a substantial correction is required for many months due to the fact that many deaths are referred to a Coroner.
Figure 2

Excess all-cause deaths by age groups, England, calendar week 40 2015–week 20 2020

Excess all-cause deaths by age groups, England, calendar week 40 2015–week 20 2020 All regions exceeded expected levels from week 12 2020, with a peak in week 15 2020. London observed the highest excess mortality rate (122.77/100,000) since the 2015/16 season and subsequently returned close to expected levels faster than the other regions by week 20, with other regions remaining above the upper 6 z-score limit at week 20 (Figure 3 and Table).
Figure 3

Excess all-cause deaths by regions, England, calendar week 40 2015–week 20 2020

Excess all-cause deaths by regions, England, calendar week 40 2015–week 20 2020

Discussion

This study describes the very high all-cause excess mortality observed in England during the current COVID-19 pandemic. The findings show that England has experienced the highest excess all-cause mortality in comparison to previous seasons since 2015/16. The excess appears to be higher than that reported in other European countries based on z-score analyses [11]. At the beginning of the winter of 2019/20, England observed low excess all-cause mortality in comparisons to previous seasons which is unusual for a winter dominated by the circulation of influenza A(H3N2). The high number of all-cause deaths observed in week 15 across all ages except the 0–14 year olds, occurred 2 weeks after the ‘Stay at home’ lockdown government guidelines were enforced on 23 March 2020 (week 13) [12]. This is also in line with the peak in deaths due to COVID-19 in England reported elsewhere [13,14]. We found that excess mortality was higher in the oldest population, ≥ 85 year olds, with cumulative mortality rates being the highest observed in the past 5 years. This coincides with this age group also experiencing the highest case detections and hospitalisations as well as higher COVID-19-confirmed deaths as a proportion of overall cases [14]. Studies in other European countries have found the same higher rates in this and other older age groups [15,16]. A recent study investigating the relative risk of COVID-19 deaths in the United States and Europe suggests that the < 65 years age group has the lowest risk [17]. This is in line with our findings of no or low excess mortality observed in the 0–14 year olds, also noted in another recent European report [18]. We present all-cause excess mortality by regions in England. London was observed to have the highest excess all-cause mortality in comparison to other regions and its own historical trends but was also the region where rapid decreases were noted despite having the highest number of cases by region [14]. This also coincides with London being the region with the highest number of cases and seroprevalence [14]. Similar regional differences have been reported by other European countries and linked to regionally higher numbers of COVID-19 deaths [16]. One of the main strengths of this study is the use of the standardised EuroMOMO algorithm, which allowed us to make comparisons with other European countries and across seasons for many years. The need for such rapid assessment of excess mortality has been advocated during this pandemic [19]. A limitation of the z-score analysis however is that it does not allow a clear comparison of the exact scale of the excess between countries, because z-scores do not translate to the same number or proportional excess in different countries. Further work will be carried out to examine the contribution of cause-specific deaths to the overall excess and understanding the contributing factors to the high excess mortality seen in all adults in England. Overall, our findings highlight the importance of monitoring excess all-cause mortality as an indicator of disease burden in situations such as the current pandemic caused by a previously-unknown pathogen, for which the impact is still difficult to assess at the present time. Continued excess mortality monitoring will help assess the effect of relaxation of lockdown measures and mortality excess that may not be directly related to COVID-19 infections.
  8 in total

1.  Excess Mortality Estimation During the COVID-19 Pandemic: Preliminary Data from Portugal.

Authors:  Paulo Jorge Nogueira; Miguel De Araújo Nobre; Paulo Jorge Nicola; Cristina Furtado; António Vaz Carneiro
Journal:  Acta Med Port       Date:  2020-04-27

2.  Significant spike in excess mortality in England in winter 2014/15 - influenza the likely culprit.

Authors:  R G Pebody; H K Green; F Warburton; M Sinnathamby; J Ellis; K Mølbak; J Nielsen; S de Lusignan; N Andrews
Journal:  Epidemiol Infect       Date:  2018-05-10       Impact factor: 4.434

3.  Mortality caused by influenza and respiratory syncytial virus by age group in England and Wales 1999-2010.

Authors:  P Hardelid; R Pebody; N Andrews
Journal:  Influenza Other Respir Viruses       Date:  2012-03-09       Impact factor: 4.380

4.  Mortality impacts of the coronavirus disease (COVID-19) outbreak by sex and age: rapid mortality surveillance system, Italy, 1 February to 18 April 2020.

Authors:  Paola Michelozzi; Francesca de'Donato; Matteo Scortichini; Manuela De Sario; Fiammetta Noccioli; Pasqualino Rossi; Marina Davoli
Journal:  Euro Surveill       Date:  2020-05

5.  European all-cause excess and influenza-attributable mortality in the 2017/18 season: should the burden of influenza B be reconsidered?

Authors:  J Nielsen; L S Vestergaard; L Richter; D Schmid; N Bustos; T Asikainen; R Trebbien; G Denissov; K Innos; M J Virtanen; A Fouillet; T Lytras; K Gkolfinopoulou; M An der Heiden; L Grabenhenrich; H Uphoff; A Paldy; J Bobvos; L Domegan; J O'Donnell; M Scortichini; A de Martino; J Mossong; K England; J Melillo; L van Asten; M Ma de Lange; R Tønnessen; R A White; S P da Silva; A P Rodrigues; A Larrauri; C Mazagatos; A Farah; A D Carnahan; C Junker; M Sinnathamby; R G Pebody; N Andrews; A Reynolds; J McMenamin; C S Brown; C Adlhoch; P Penttinen; K Mølbak; T G Krause
Journal:  Clin Microbiol Infect       Date:  2019-02-18       Impact factor: 8.067

6.  Pooling European all-cause mortality: methodology and findings for the seasons 2008/2009 to 2010/2011.

Authors:  J Nielsen; A Mazick; N Andrews; M Detsis; T M Fenech; V M Flores; A Foulliet; B Gergonne; H K Green; C Junker; B Nunes; J O'Donnell; A Oza; A Paldy; R Pebody; A Reynolds; T Sideroglou; B E Snijders; F Simon-Soria; H Uphoff; L VAN Asten; M J Virtanen; F Wuillaume; K Mølbak
Journal:  Epidemiol Infect       Date:  2012-11-27       Impact factor: 4.434

7.  Excess all-cause mortality during the COVID-19 pandemic in Europe - preliminary pooled estimates from the EuroMOMO network, March to April 2020.

Authors:  Lasse S Vestergaard; Jens Nielsen; Lukas Richter; Daniela Schmid; Natalia Bustos; Toon Braeye; Gleb Denissov; Tatjana Veideman; Oskari Luomala; Teemu Möttönen; Anne Fouillet; Céline Caserio-Schönemann; Matthias An der Heiden; Helmut Uphoff; Theodore Lytras; Kassiani Gkolfinopoulou; Anna Paldy; Lisa Domegan; Joan O'Donnell; Francesca De' Donato; Fiammetta Noccioli; Patrick Hoffmann; Telma Velez; Kathleen England; Liselotte van Asten; Richard A White; Ragnhild Tønnessen; Susana P da Silva; Ana P Rodrigues; Amparo Larrauri; Concepción Delgado-Sanz; Ahmed Farah; Ilias Galanis; Christoph Junker; Damir Perisa; Mary Sinnathamby; Nick Andrews; Mark O'Doherty; Diogo Fp Marquess; Sharon Kennedy; Sonja J Olsen; Richard Pebody; Tyra G Krause; Kåre Mølbak
Journal:  Euro Surveill       Date:  2020-07

8.  COVID-19: a need for real-time monitoring of weekly excess deaths.

Authors:  David A Leon; Vladimir M Shkolnikov; Liam Smeeth; Per Magnus; Markéta Pechholdová; Christopher I Jarvis
Journal:  Lancet       Date:  2020-04-22       Impact factor: 79.321

  8 in total
  21 in total

1.  Estimating under-recognized COVID-19 deaths, United States, march 2020-may 2021 using an excess mortality modelling approach.

Authors:  A Danielle Iuliano; Howard H Chang; Neha N Patel; Ryan Threlkel; Krista Kniss; Jeremy Reich; Molly Steele; Aron J Hall; Alicia M Fry; Carrie Reed
Journal:  Lancet Reg Health Am       Date:  2021-07-13

2.  Non-COVID outcomes associated with the coronavirus disease-2019 (COVID-19) pandemic effects study (COPES): A systematic review and meta-analysis.

Authors:  Vincent Issac Lau; Sumeet Dhanoa; Harleen Cheema; Kimberley Lewis; Patrick Geeraert; David Lu; Benjamin Merrick; Aaron Vander Leek; Meghan Sebastianski; Brittany Kula; Dipayan Chaudhuri; Arnav Agarwal; Daniel J Niven; Kirsten M Fiest; Henry T Stelfox; Danny J Zuege; Oleksa G Rewa; Sean M Bagshaw
Journal:  PLoS One       Date:  2022-06-24       Impact factor: 3.752

3.  Specificity and positive predictive value of SARS-CoV-2 nucleic acid amplification testing in a low-prevalence setting.

Authors:  Jordan P Skittrall; Michael Wilson; Anna A Smielewska; Surendra Parmar; Mary D Fortune; Dominic Sparkes; Martin D Curran; Hongyi Zhang; Hamid Jalal
Journal:  Clin Microbiol Infect       Date:  2020-10-14       Impact factor: 8.067

4.  Real-time monitoring shows substantial excess all-cause mortality during second wave of COVID-19 in Europe, October to December 2020.

Authors:  Sarah K Nørgaard; Lasse S Vestergaard; Jens Nielsen; Lukas Richter; Daniela Schmid; Natalia Bustos; Toon Braye; Maria Athanasiadou; Theodore Lytras; Gleb Denissov; Tatjana Veideman; Oskari Luomala; Teemu Möttönen; Anne Fouillet; Céline Caserio-Schönemann; Matthias An der Heiden; Helmut Uphoff; Kassiani Gkolfinopoulou; Janos Bobvos; Anna Paldy; Naama Rotem; Irene Kornilenko; Lisa Domegan; Joan O'Donnell; Francesca De Donato; Matteo Scortichini; Patrick Hoffmann; Telma Velez; Kathleen England; Neville Calleja; Liselotte van Asten; Lenny Stoeldraijer; Richard A White; Trine H Paulsen; Susana P da Silva; Ana P Rodrigues; Petra Klepac; Metka Zaletel; Mario Fafangel; Amparo Larrauri; Inmaculada León; Ahmed Farah; Ilias Galanis; Christoph Junker; Damir Perisa; Mary Sinnathamby; Nick Andrews; Mark G O'Doherty; David Irwin; Sharon Kennedy; Jim McMenamin; Cornelia Adlhoch; Nick Bundle; Pasi Penttinen; Jukka Pukkila; Richard Pebody; Tyra G Krause; Kåre Mølbak
Journal:  Euro Surveill       Date:  2021-01

5.  Excess mortality from COVID-19: weekly excess death rates by age and sex for Sweden and its most affected region.

Authors:  Karin Modig; Anders Ahlbom; Marcus Ebeling
Journal:  Eur J Public Health       Date:  2021-02-01       Impact factor: 3.367

6.  Assessing the Country-Level Excess All-Cause Mortality and the Impacts of Air Pollution and Human Activity during the COVID-19 Epidemic.

Authors:  Yuan Meng; Man Sing Wong; Hanfa Xing; Mei-Po Kwan; Rui Zhu
Journal:  Int J Environ Res Public Health       Date:  2021-06-26       Impact factor: 3.390

7.  Excess all-cause mortality during the first wave of the COVID-19 epidemic in France, March to May 2020.

Authors:  Anne Fouillet; Isabelle Pontais; Céline Caserio-Schönemann
Journal:  Euro Surveill       Date:  2020-08

8.  Timely monitoring of total mortality associated with COVID-19: informing public health and the public.

Authors:  Lasse S Vestergaard; Kåre Mølbak
Journal:  Euro Surveill       Date:  2020-08

9.  The world is its own best model: modelling and future pandemic planning in dentistry.

Authors:  Mark-Steven Howe
Journal:  Br Dent J       Date:  2020-12-11       Impact factor: 2.727

10.  Local mortality estimates during the COVID-19 pandemic in Italy.

Authors:  Augusto Cerqua; Roberta Di Stefano; Marco Letta; Sara Miccoli
Journal:  J Popul Econ       Date:  2021-06-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.